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2 Diabetes Mellitus: Results from a Pooled Analysis
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Aleksandra Vlajnic, MD,§ Ling Gao, MS,§ and Jeffrey Halter, MD*
OBJECTIVES: To compare the safety and efficacy of add-
ing insulin glargine or neutral protamine Hagedorn (NPH)
insulin to existing oral antidiabetic drug (OAD) regimens
in adults with type 2 diabetes mellitus.
DESIGN: Pooled analysis of data from five randomized
controlled trials with similar designs.
SETTING: Three hundred forty-two centers in more than
30 countries worldwide.
PARTICIPANTS: Randomly selected individuals aged ≤80
with a body mass index ≤40 kg/m2 and a glycosylated
hemoglobin (HbA1c) level of 7.5% to 12.0%.
MEASUREMENTS: Fixed- and random-effects models
were used to compare outcomes after 24 or 28 weeks of
treatment (insulin glargine, n = 1,441; NPH insulin,
n = 1,254) according to age (65, n = 604 vs < 65,
n = 2,091) and age based on treatment (e.g.,  65 receiv-
ing insulin glargine vs NPH insulin). Outcomes included
change in HbA1c, fasting blood glucose (FBG), insulin
dose, and hypoglycemia incidence and event rates.
RESULTS: At end point, participants aged 65 and older
receiving insulin glargine had greater reductions in HbA1c
and FBG than those receiving similar doses of NPH insu-
lin. In contrast, for participants younger than 65, there
were no statistically significant differences in reductions in
HbA1c or FBG between insulin glargine and NPH insulin.
Daytime hypoglycemia rates were similar in all groups,
although the rates of nocturnal symptomatic and severe
hypoglycemia were lower with insulin glargine than NPH
insulin.
CONCLUSION: Addition of insulin glargine to oral an-
tidiabetic drugs in older adults with poor glycemic control
may have modestly better glycemic benefits than adding
NPH insulin, with low risk of hypoglycemia. J Am Geriatr
Soc 60:51–59, 2012.
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Nearly one-quarter of all Americans aged 60 and older(12.2 million) have diabetes mellitus.1 The prevalence
of diabetes mellitus in older adults is expected to rise to
epidemic proportions in future decades because of the
aging of the population; by 2050, the prevalence of diag-
nosed diabetes mellitus is expected to increase 252% in
women aged 65 to 74 and 537% in men aged 75 and
older from rates reported in 2000.2
The complex health conditions and susceptibility to
medication adverse effects of older adults complicates their
diabetes mellitus treatment, particularly with respect to
glycemic control. The American Geriatrics Society (AGS)3
and the American Diabetes Association (ADA)4 have rec-
ommended individualization of glycemic targets for older
adults based on their health status and risk of adverse
effects. For healthy older adults with few comorbid condi-
tions, the standard glycemic target of the AGS and the
ADA is a glycosylated hemoglobin (HbA1c) level of 7.0%.
Although most individuals with type 2 diabetes mell-
itus are initially treated with oral antihyperglycemic
agents, progressive loss of pancreatic beta-cell function
and decreased insulin sensitivity are often associated with
increasing levels of fasting blood glucose (FBG) and
HbA1c.5,6 Thus, many people eventually require exoge-
nous insulin therapy to achieve and maintain recom-
mended glycemic control targets.5–7 The rate of insulin
initiation in people with type 2 diabetes mellitus has been
estimated to be low, varying from 1%8 to 5.8%9 per year.
Risk of hypoglycemia is often a deterrent for healthcare
providers to initiate insulin treatment, and people with
diabetes mellitus are often reluctant to use insulin.10–12
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Despite the availability of various forms of insulin
with different pharmacological properties, there has been
limited analysis of the comparative safety and effectiveness
of insulin regimens in older adults. For older adults with
type 2 diabetes mellitus and suboptimal glycemic control
while taking oral antidiabetic drug (OAD) therapy, find-
ings from previous studies support the addition of insulin
glargine as an alternative to simply increasing OAD
dosage.13
Insulin glargine, a long-acting recombinant human
insulin analog with a 24-hour action profile and no signifi-
cant peak,14 is thought to be a potential insulin of choice
for older adults. Previous randomized controlled trials not
targeting older adults have consistently shown that people
treated with insulin glargine can attain similar glycemic
control with a lower risk of hypoglycemia than those
treated with other forms of insulin.15–20 The goal of the
current study was to compare the safety and efficacy of
adding insulin glargine with that of adding neutral prot-
amine Hagedorn (NPH) insulin in older and younger
adults with poorly controlled diabetes mellitus while tak-
ing OADs. Given that there are no randomized controlled
trials specifically designed to assess these differences
in older adults, a pooled analysis of five sanofi-aventis-
sponsored multisite randomized clinical trials with similar
research methodologies was performed.
METHODS
A pooled analysis was performed of participants in five
international randomized controlled trials (RCTs) with
similar study designs15,21–24 to examine the effects of age
and insulin treatment in a large population of patients
with type 2 diabetes mellitus. All participant-level data
from the five selected trials were combined for analyses.
Study Selection
Twenty-two sanofi-aventis-sponsored RCTs in adults with
type 2 diabetes mellitus were screened for inclusion in this
analysis. Studies were included if they compared the safety
and efficacy of adding insulin glargine with that of adding
NPH insulin in participants with known type 2 diabetes
mellitus who had suboptimal glycemic control while taking
OADs and met the following criteria:
● Studies were prospective, randomized, controlled, and of
24 weeks’ duration and longer.
● Participants had poor glycemic control based on high
FBG or HbA1c levels.
● After randomization, basal insulin (insulin glargine or
NPH insulin) was given once daily, with no prandial or
bolus insulin administration.
● Basal insulin was titrated based on fasting glucose
targets.
● Participants continued to take their original OADs or
another OAD predetermined by the trial.
Studies were conducted according to the Good Clini-
cal Practice Guidelines and in accordance with the Decla-
ration of Helsinki. All participants were relatively healthy
and active, with few comorbidities. All participants must
have had the ability to understand and willingness to
perform self-administered insulin injections and self-moni-
toring of blood glucose multiple times per day.
Five trials met the above criteria and had been
conducted as multicenter, open-label RCTs in the United
States, Canada, Latin America, Europe, and Asia between
1999 and 2002.15,21–24
Study Participants
Participant enrollment criteria for each of the trials are
summarized in Table 1. Participants were aged ≤80 and
had a body mass index (BMI) ≤40 kg/m2 and a HbA1c
level between 7.5% and 12.0% at randomization. Partici-
pants in two trials continued their baseline OADs, whereas
those in the other three trials were maintained on stable
doses of glimepiride. Major exclusion criteria for the five
trials were similar and included pregnancy, recent insulin
use, history of ketoacidosis, and inability to recognize
hypoglycemia.
Intervention
After randomization, all participants received once-daily
administration of insulin glargine or NPH insulin at
bedtime or before breakfast. Four studies15,17,22,23 exam-
ined insulin treatment over 24 weeks, and one24 had a
28-week treatment phase. During the treatment phase,
the insulin dose was titrated on a predefined regimen
based on self-measured FBG using standard meters and
self-reported hypoglycemia episodes. Participants submit-
ted blood samples to have their fasting plasma glucose
(FPG) periodically measured in each study’s central labo-
ratory (studies 4001, 4013, 3102, and 4002) or a local
accredited laboratory (study 4012). HbA1c levels were
measured in laboratories using the standardized Diabetes
Control and Complications Trial method (studies 3102,
4002, 4012, and 4013) or the comparable BioRad DIA-
MAT method (study 4001), where the normal range was
4% to 6%.
Outcomes Assessed
The efficacy of insulin glargine and NPH insulin was
measured according to reduction in HbA1c and FBG and
change in insulin dose from baseline to end of treatment.
Safety was measured based on symptomatic and
severe hypoglycemia events during the treatment period.
Symptomatic hypoglycemia was defined for the pooled
data as self-monitored blood glucose less than 70 mg/dL
(<3.89 mmol/L). Nocturnal hypoglycemia was defined as
hypoglycemia that occurred while participants were
asleep, after bedtime following the evening injection and
before waking up in the morning. Cases of severe hypo-
glycemia were identified from events meeting criteria as
defined in each of the individual studies (Table 1). Severe
hypoglycemia was defined as hypoglycemic symptoms
requiring the assistance of another person; prompt recov-
ery after oral carbohydrate, intravenous glucose, or gluca-
gon administration; or a blood glucose level less than
50 mg/dL (<2.78 mmol/L) in four studies or less than
56 mg/dL (<3.11 mmol/L) in one study (data were con-
verted from plasma glucose).15
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Statistical Analysis
The intention-to-treat (ITT) population included all par-
ticipants who received a dose of study medication
(N = 2,695); these participants were included in the safety
comparisons. After six participants who did not have
HbA1c, FBG, or insulin dose measurements during the
posttreatment phase were excluded, the remaining 2,689
participants constituted the modified ITT (mITT) popula-
tion. Results for HbA1c, FBG, and insulin dose were based
on participants in the mITT population who had measure-
ments available at baseline and end point (week 24 or 28)
for each of these variables individually (n = 2,644 for
HbA1c, n = 2,669 for FBG, and n = 2,684 for insulin
dose). Blood glucose values were converted from FPG to
FBG for two studies (3102 and 400215) for pooling using
0.875 as the multiplier.
For the glycemic efficacy outcomes of interest, fixed-
and random-effects models were used to compare all par-
ticipants according to treatment (insulin glargine vs NPH
insulin) and age category ( 65 vs <65) separately and
then according to treatment and age groups together.
Age-by-treatment interactions were also examined. The
fixed-effects models included baseline values (HbA1c,
FBG, insulin dose for each respective analysis), insulin
dose at randomization, and duration of diabetes mellitus
as covariates and treatment, age category, age by treat-
ment and study as factors. The interactions of study by
age category, study by treatment, study by baseline, treat-
ment by age category, treatment by baseline, and age cate-
gory by baseline values were included in the models if they
were statistically significant (P < .01). The random-effects
models included baseline values, insulin dose at randomi-
zation, duration of diabetes mellitus, treatment, age cate-
gory, and age by treatment as fixed effects, with study,
study by age category, and study by treatment as random
effects. The interactions between treatment or age category
and baseline values were included as fixed effects, and the
interactions between study and treatment or baseline val-
ues were included as random effects if they were statisti-
cally significant (P < .01). Heterogeneity tests (e.g., one-
way t-test for the difference between two treatment groups
according to age category and study, and analysis of
covariance models for efficacy variables at treatment end
point and change from baseline to end point between
treatment groups and age categories according to trials)
were conducted to assess model fit.
For safety outcomes, descriptive analysis was per-
formed for incidence (percentage of participants with
1 symptomatic or severe hypoglycemia events) and
event rates (number of symptomatic or severe hypoglyce-
mic events per person-year). The Cochran–Mantel–
Haenszel test was performed for difference in incidence
between treatment arms or age categories. A rank analy-
sis of variance including trials as factors was used to
assess the difference in event rate between treatment
groups or age categories. Hypoglycemia incidence was
analyzed using fixed- and random-effects models using a
binomial distribution logit link (SAS version 9.1.3,
PROC GENMOD, SAS Institute, Inc., Cary, NC). Hypo-
glycemia event rates were analyzed using fixed- and ran-
dom-effects models using a Poisson distribution log link
(SAS version 9.1.3, PROC GENMOD), which accounted
for overdispersion. Both fixed-effects models included
factors of treatment, baseline HbA1c, BMI, duration of
diabetes mellitus, and insulin dose at randomization; age
category; study; and treatment by age category. The ran-
dom-effects models included treatment, baseline HbA1c,
BMI, duration of diabetes mellitus, and insulin dose
at randomization; age category; and treatment by age
category as fixed effects, with study and study by age
category as random effects.
For glycemic efficacy and safety outcomes, results
from the fixed-effects models were applied if they agreed
with that from the random-effects model; otherwise, the
results from the random-effects models were applied as the
conservative analysis. In cases of very few hypoglycemia
events in a treatment arm and age category, such as severe
hypoglycemia, only results from the fixed-effects model
were applied. For transparency, nominal (unadjusted, raw)
values were reported along with modeled (adjusted) values
and statistical comparisons.
RESULTS
Baseline Characteristics
Two thousand six hundred ninety-five participants from
the five selected sanofi-aventis-sponsored trials were
included in the ITT population; their demographic and
diabetes mellitus characteristics at baseline are shown in
Table 2. Participants younger than 65 (n = 2,091) and
aged 65 and older (n = 604) were compared. For each of
these two participant groups, those who received insulin
glargine and NPH insulin had a similar mean age, per-
centage of men, mean weight, and mean BMI and no sta-
tistical difference in prior use of OADs. For participants
aged 65 and older, the insulin glargine group had higher
baseline HbA1c, FBG, and initial insulin dose at random-
ization than did the NPH insulin group. In participants
younger than 65, the insulin glargine group had a shorter
duration of diabetes mellitus than did the NPH insulin
group and received a higher initiating insulin dose at
randomization.
Efficacy: Glycemic Control and Insulin Dose
Treatment Effect
Overall, participants treated with insulin glargine and
NPH insulin had similar nominal mean reductions in
HbA1c (1.3% vs 1.2%), FBG (4.7 mmol/L vs
4.3 mmol/L), and insulin dose (Δ = 23 U/d vs 21 U/d)
at the end of treatment. After 24 or 28 weeks of treat-
ment, mean HbA1c was 7.7% and 7.7% (adjusted differ-
ence 0.12%, 95% CI = 0.28–0.04, P = .11), mean
FBG was 6.5 and 6.6 mmol/L (adjusted difference
0.2 mmol/L, 95% CI = 0.53–0.09, P = .12), and mean
daily insulin doses were 36 and 33 U (adjusted difference
1.4 U, 95% CI = 1.57–4.38, P = .26) for the insulin
glargine and the NPH insulin groups, respectively. Differ-
ences between the treatment groups reached statistical
significance for HbA1c (P = .004) and FBG (P = .001) in
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the fixed-effects but not the more-conservative random-
effects model.
Age Effect
There was no statistical difference between the age groups
in HbA1c, FBG, or insulin dose overall. At end point, mean
HbA1c was 7.7% in the group younger than 65 and 7.8%
in the group aged 65 and older. Nominal mean HbA1c
reductions were 1.3% and 1.1%, respectively (adjusted
difference 0.05%, 95% CI = 0.15–0.05, P = .33). FBG
decreased 4.48 and 4.51 mmol/L to mean values of
6.6 mmol/L in those younger than 65 and 6.4 mmol/L in
those aged 65 and older (adjusted difference 0.17 mmol/L,
95% CI = 0.01–0.35, P = .06). Mean insulin dose at end
point was 36 U in the younger group and 29 U in the older
group. The amount of daily insulin used with titration over
the course of 24 to 28 weeks increased by 24 U and 16 U,
respectively. Differences between age groups were signifi-
cant in the fixed-effects model (P < .001) but not in the
random-effects model (adjusted mean difference 5.8 U,
95% CI = 0.98–12.64, P = .08).
Treatment by Age Effect
There were statistically significant age by treatment inter-
actions for HbA1c (P = .009) and FBG (P = .01) but not
insulin dose (P = .27) at end point.
Participants aged 65 and older treated with insulin
glargine had significantly greater decreases in HbA1c
(1.5% vs 1.1%), and FBG (4.7 vs 4.1 mmol/L)
from baseline (P < .001 for both), with similar changes in
insulin dose at the end of the treatment (17 U/d for both),
compared to those treated with NPH insulin (Figure 1).
However, in participants younger than 65, the two treat-
ment groups had similar changes on all three measures
(HbA1c, 1.4% vs 1.3%; FBG, 4.3 vs 4.2 mmol/L;
and insulin dose, 24 vs 22 U at end point for insulin glar-
gine vs NPH insulin, respectively, Figure 1). Mean values
at end point (unadjusted and after adjustment) and statisti-
cal comparisons are presented in Table 3.
Participants receiving insulin glargine aged 65 and
older had similar change in HbA1c (1.34% vs 1.45%)
as those younger than 65 but greater change in FBG (4.3
vs 4.7 mmol/L, P = .002) and less change in insulin dose
(24 vs 17 U/d, P = .01) at end point. Conversely, partici-
pants receiving NPH insulin aged 65 and older had sig-
nificantly less mean change in HbA1c at end point than
those younger than 65 (1.1% vs 1.3%, P = .02) and
no statistically significant difference in FBG (4.1 vs
4.2 mmol/L, P = .59) or insulin dose changes (17 vs
22 U, P = .07) from baseline to end point (Figure 1 and
Table 3).
Safety: Incidence and Event Rates of Symptomatic and
Severe Hypoglycemia
Treatment Effect
The incidence and event rates of symptomatic and severe
hypoglycemia for each age group based on insulin treat-
ment are presented in Table 4. Overall, participants receiv-
ing insulin glargine (n = 1,441) and those receiving NPH
insulin (n = 1,254) had similar incidence of daytime symp-
tomatic (38% vs 41%, odds ratio (OR) = 0.92, 95%
CI = 0.77–1.09, P = .31) and severe (1.3% vs 1.2%,
OR = 1.31, 95% CI = 0.58–2.94, P = .50) hypoglycemia.
The insulin glargine group had lower incidence of noctur-
nal symptomatic (20% vs 34%, OR = 0.61, 95%
CI = 0.42–0.89, P = .008) and severe (0.8% vs 2.2%,
Table 2. Participant Characteristics at Baseline (Intention-to-Treat Group)
Participant Characteristic
Aged < 65 (n = 2,091) Aged  65 (n = 604)
Insulin Glargine
(n = 1,112)
NPH Insulin
(n = 979)
Insulin Glargine
(n = 329)
NPH Insulin
(n = 275)
Age, mean ± SD 53 ± 7.7 54 ± 7.1 69 ± 3.4 69 ± 3.4
Male, n (%) 580 (52) 486 (50) 163 (50) 148 (54)
Weight, kg, mean ± SD 79.0 ± 19.3 78.4 ± 19.3 75.4 ± 16.3 74.7 ± 17.5
Body mass index, kg/m2, mean ± SD 28.3 ± 5.2 28.4 ± 5.2 27.7 ± 4.4 27.4 ± 4.6
Diabetes mellitus duration, years, mean ± SD 9.2 ± 5.9* 9.8 ± 5.9 12.3 ± 7.7 11.5 ± 6.3
Glycosylated hemoglobin, %, mean ± SD 8.9 ± 1.0 9.0 ± 1.0 9.0 ± 1.0* 8.8 ± 0.9
FBG, mmol/L, mean ± SD† 11.2 ± 3.0 11.0 ± 2.9 11.2 ± 3.1* 10.7 ± 3.0
Insulin dose at randomization, U/d, mean ± SD 13 ± 8.7* 12 ± 7.1 15 ± 9.2* 12 ± 7.8
Prior use of OADs, n (%)‡
Metformin only 397 (40.6) 407 (48.0) 91 (29.7) 98 (39.7)
Sulfonylureas only 507 (51.9) 388 (45.8) 187 (61.1) 125 (50.6)
Thiazolidinediones only 5 (0.5) 2 (0.2) 1 (0.3) 0 (0.0)
Metformin and sulfonylurea 6 (0.6) 3 (0.4) 4 (1.3) 4 (1.6)
Other OADs only 61 (6.2) 47 (5.5) 23 (7.5) 20 (8.1)
* P < .05 versus neutral protamine Hagedorn (NPH) insulin within age category.
† Two of the studies (3102 and 400215) measured fasting plasma glucose values, which were then converted to fasting blood glucose (FBG) for pooling
using 0.875 as the multiplier.
‡ Excluding participants from study 3102, in which the information is not available in English.
OADs = oral antidiabetic drugs; SD = standard deviation.
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OR = 0.38, 95% CI = 0.19–0.77, P = .007) hypoglycemia.
The same pattern was true for hypoglycemia event rates.
Age Effect
Combining the two insulin treatment groups, participants
younger than 65 and those aged 65 and older had similar
incidences of daytime and nocturnal symptomatic hypogly-
cemia (daytime, 39% vs 41%, OR = 0.87, 95% CI = 0.71
–1.07, P = .18; nocturnal, 26% vs 27%, OR = 0.87, 95%
CI = 0.69–1.10, P = .24), and severe (daytime, 1.2% vs
1.2%, OR = 1.04, 95% CI = 0.43–2.49, P = .94; noctur-
nal, 1.4% vs 1.8%, OR = 0.68, 95% CI = 0.32–1.43,
P = .30; Table 4). Only nocturnal symptomatic hypoglyce-
mia event rate was significantly higher in participants aged
65 and older than in those younger than 65 (1.98 vs 2.24
events/participant per year, rate ratio (RR) = 0.73, 95%
CI = 0.46–1.15, P = .047).
Treatment by Age Effect
There were no treatment by age interactions for any of the
hypoglycemia measures. There were no statistical differ-
ences between groups on daytime hypoglycemia measures
and no differences between treatments in the group of
patients aged 65 and older, although participants younger
than 65 treated with insulin glargine had lower incidence
and event rates of nocturnal symptomatic and severe hypo-
glycemia than those receiving NPH insulin (nocturnal
symptomatic: incidence: 20% vs 34%, OR = 0.57, 95%
CI = 0.39–0.85, P = .005, event rate: 1.27 vs 2.78 events/
participant per year, RR = 0.66, 95% CI = 0.45–0.97,
P = .03; nocturnal severe: incidence: 0.7% vs 2.2%,
OR = 0.35, 95% CI = 0.15–0.82, P = .01, event rate:
0.02 vs 0.07 events/participant per year, RR = 0.27, 95%
CI = 0.11–0.071, P = .007; Table 4).
DISCUSSION
Consistent with studies in adults of any age with type 2
diabetes mellitus, as summarized in two meta-analyses,25,26
this pooled analysis indicates that adding insulin glargine
in older adults on an existing OAD regimen is more effec-
tive in reducing HbA1c and FBG during 24 or 28 weeks
of treatment than adding a single daily dose of NPH insu-
lin, and elicits less nocturnal symptomatic and severe
hypoglycemia. These findings are also consistent with the
pharmacological properties of these two insulins; NPH
insulin is an intermediate-acting insulin that can last up to
20 hours, whereas insulin glargine is a long-acting insulin
that usually lasts up to 24 hours.14,27
The present study also found that, with lower doses of
insulin glargine, older adults ( 65) can achieve glycemic
improvements greater than or similar to those of younger
adults (<65) (Table 3). Although younger and older study
participants were similar in terms of FBG and HbA1c at
baseline, potential contributing factors not assessed in this
study included poorer renal function and less physical
activity in older than in younger adults.28
Daytime hypoglycemia occurred with equal prevalence
in all groups, with an incidence of symptomatic hypoglyce-
mia of approximately 40%. There was no greater risk of
symptomatic or severe daytime hypoglycemia in adults
aged 65 and older than in younger adults when insulin
glargine- and NPH insulin-treated subgroups were ana-
lyzed together or separately. Nocturnal symptomatic hypo-
glycemia event rates were higher in the older participants
when the two treatment groups were combined and higher
in the NPH group when the two age groups were com-
bined. Nocturnal symptomatic and severe hypoglycemia
were higher in the NPH group than in the insulin glargine
group whether measured as incidence or event rates. This
difference seems to be driven by the younger group, in
which all measures were significantly greater in the NPH
insulin group. The older group receiving NPH insulin also
experienced more nocturnal hypoglycemia, but this did not
reach statistical significance.
Rates of severe hypoglycemia in the current analysis
were low and consistent with those of previous clinical
trials of insulin therapy in adults with type 2 diabetes
mellitus aiming to achieve a mean HbA1c of
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Figure 1. Adjusted mean (standard error) reduction from
baseline to end point in glycosylated hemoglobin (HbA1c)
(A), fasting blood glucose (FBG) (B), and insulin dose (C) for
all participants (modified intention-to-treat group). P-values
shown in the figure are significant differences for insulin glar-
gine versus neutral protamine Hagedorn (NPH) insulin in
participants aged 65 and older. *P < .005 between age cate-
gories in NPH insulin–treated participants. †P < .01 between
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approximately 7.0%.18,29–32 Severe hypoglycemic events,
although rare, can lead to neurological impairment, sei-
zures, coma, and death,33 and are a potential deterrent to
the use of insulin in older adults. Studies of hypoglycemic
risk during insulin use in this potentially vulnerable popu-
lation are limited. The current ADA treatment guidelines
consider hypoglycemia avoidance important in the treat-
ment of type 2 diabetes mellitus, particularly in older
adults.4 These guidelines suggest that treatment decisions,
such as basal insulin selection, should be individualized to
minimize the risk of hypoglycemia for each person.
One of the strengths of the current study is that, to
the knowledge of the authors, this is the first analysis spe-
cifically evaluating the efficacy and safety of adding insulin
glargine or NPH insulin to an OAD regimen in older
adults. Such analyses have not been done in the past
because of the limited number of older adults being
included in individual randomized controlled trials.
Another strength is that the analysis is based upon individ-
ual participants’ data from the original RCTs instead of
using published data aggregates. Pooled analysis from indi-
vidual trials’ published data is usually insufficient to calcu-
late a pooled estimate because published estimates are
based on heterogeneous populations, different study
designs, and different statistical models.34 The current
pooled analysis of individual participants’ data minimized
the heterogeneity of the trials and may have produced
more-reliable results.
One limitation of this study is that participants were
given only once-daily doses of NPH insulin, whereas in
clinical settings, many people receive NPH insulin twice
per day or with mixed insulin injections.35 A previous
study compared the administration of insulin glargine with
OADs with switching participants to twice-daily premixed
70% NPH and 30% regular insulin (70/30) without
OADs.31 Of the 130 insulin-naive participants aged 65
and older with baseline HbA1c of 7.5% to 10.5% with
OADs, the addition of insulin glargine was found to be
more effective at glycemic control, with less confirmed
hypoglycemia, than was twice-daily 70/30 alone (3.7 vs
9.1 events/person per year). Thus, the estimation in the
current study of hypoglycemia risk in the NPH insulin-
treated participants may be lower than what may be seen
in clinical dosing.
Another limitation of the current analyses is that,
because of study inclusion and exclusion criteria, partici-
pants were likely to be more functional and have fewer
comorbidities than the general older adult population. Of
community-dwelling individuals aged 65 and older, 62%
have two or more chronic medical conditions,36 and many
also have co-occurring geriatric syndromes, such as urinary
incontinence and falls.37 Older adults may have less-
intense hypoglycemic symptoms and may be less aware of
their hypoglycemia and consequently be less likely to per-
form effective self-treatment of hypoglycemia.33,38 Case
reports have found that older adults with hypoglycemia
and cognitive impairment may present with atypical hypo-
glycemia symptoms and may have hypoglycemia unaware-
ness.39,40 Based on a review of these issues, the AGS has
recommended HbA1c goals of 7.0% or less for older
adults with good functional status and a less-stringent
HbA1c goal of 8.0% for frail adults with a life expectancy
of less than 5 years.3 The ADA treatment guidelines echo
this.4 Future studies should evaluate the safety and efficacy
of different insulin regimens in older adults with various
functional statuses and multiple comorbidities.
In conclusion, the present analyses suggest that, in
appropriately selected older adults with type 2 diabetes
Table 4. Incidence and Event Rates of Symptomatic (Self-Monitored Blood Glucose <70 mg/dL) and Severe Hypo-
glycemia in Each Age Group and Overall According to Age and Insulin Treatment
Hypoglycemia
Aged < 65 Aged  65 Overall
Insulin
Glargine
(n = 1,112)
NPH Insulin
(n = 979)
Overall
(n = 2,091)
Insulin
Glargine
(n = 329)
NPH Insulin
(n = 275)
Overall
(n = 604)
Insulin
Glargine
(n = 1,441)
NPH Insulin
(n = 1,254)
Daytime hypoglycemia incidence, n (%)
Symptomatic 422 (38) 403 (41) 825 (39) 132 (40) 117 (43) 249 (41) 554 (38) 520 (41)
Severe 15 (1.4) 11 (1.1) 26 (1.2) 3 (0.9) 4 (1.5) 7 (1.2) 18 (1.3) 15 (1.2)
Daytime rate, events/person per year
Symptomatic 3.38 3.80 3.58 3.12 3.67 3.37 3.32 3.77
Severe 0.03 0.04 0.03 0.03 0.04 0.03 0.03 0.04
Nocturnal hypoglycemia incidence, n (%)
Symptomatic 222 (20)*† 331 (34) 553 (26) 69 (21) 92 (33) 161 (27) 291 (20)‡ 423 (34)
Severe 8 (0.7)* 21 (2.2) 29 (1.4) 4 (1.2) 7 (2.6) 11 (1.8) 12 (0.8)‡ 28 (2.2)
Nocturnal rate, events/person per year
Symptomatic 1.27* 2.78 1.98 1.46 3.16 2.24§ 1.32‡ 2.86
Severe 0.02* 0.07 0.04 0.06 0.12 0.08 0.03‡ 0.08
Incidence is the percentage of participants with at least 1 symptomatic or severe hypoglycemic event.
Rate is the number of symptomatic or severe hypoglycemic events/person per year. Data shown are raw data. Statistical comparisons were performed using
analyses with fixed- and random-effects models, adjusted for treatment, baseline glycosylated hemoglobin, duration of diabetes mellitus, insulin dose at
randomization, body mass index, age, and treatment by age as fixed effects in both models, and study and study by age as fixed effects in the fixed-effects
models and as random effects in the random-effects models.
* P < .05 insulin glargine versus neutral protamine Hagedorn (NPH) insulin in the <65 group; † P < .05 insulin glargine in the <65 group versus insulin
glargine in the  65 group;‡ P < .05 insulin glargine versus NPH insulin overall;§ P < .05 aged 65 versus <65.
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mellitus, adding insulin glargine to an existing OAD
regimen may be more effective than adding NPH insulin,
with a low risk for inducing hypoglycemia.
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